Cargando…
Bioactive natural compounds as potential medications for osteogenic effects in a molecular docking approach
Bone defect repair and fracture healing are critical challenges in clinical treatments. Bioactive natural compounds are potential resources for medications for osteogenic effects. We have identified icariin, the effective ingredient of Epimedium pubescens, to promote osteogenic differentiation of bo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449150/ https://www.ncbi.nlm.nih.gov/pubmed/36091759 http://dx.doi.org/10.3389/fphar.2022.955983 |
_version_ | 1784784228350689280 |
---|---|
author | Wu, Yuqiong Liu, Yulan Xu, Yuanjin Zheng, Ao Du, Jiahui Cao, Lingyan Shi, Junfeng Jiang, Xinquan |
author_facet | Wu, Yuqiong Liu, Yulan Xu, Yuanjin Zheng, Ao Du, Jiahui Cao, Lingyan Shi, Junfeng Jiang, Xinquan |
author_sort | Wu, Yuqiong |
collection | PubMed |
description | Bone defect repair and fracture healing are critical challenges in clinical treatments. Bioactive natural compounds are potential resources for medications for osteogenic effects. We have identified icariin, the effective ingredient of Epimedium pubescens, to promote osteogenic differentiation of bone mesenchymal stem cells (BMSCs) and repair bone defects. To explore more natural compounds with the potential modality for bone repair, in the present study, we employed an icariin-induced gene expression pattern as an osteogenic model and screened the Connectivity Map database for small molecules with gene expression signatures similar to this model. We verified the effectiveness of this molecule docking approach by introducing hydroxycholesterol, the second highest score of the similarity to icariin, into the osteoinductive experiments in vitro and demonstrated its excellent osteogenic effect on BMSCs compared with a BMP-2-positive control group. Based on the compatible result of hydroxycholesterol, subsequently, ginsenoside Rb1 was chosen as the most drug-like natural compound among the molecule docking results from icariin. Finally, ginsenoside Rb1 was demonstrated to promote the expression of osteoblastic genes and ALP activity in vitro and repair the calvarial defect of rats in vivo. The study aimed to provide diverse choices for clinical application in bone repair and functional regeneration. |
format | Online Article Text |
id | pubmed-9449150 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94491502022-09-08 Bioactive natural compounds as potential medications for osteogenic effects in a molecular docking approach Wu, Yuqiong Liu, Yulan Xu, Yuanjin Zheng, Ao Du, Jiahui Cao, Lingyan Shi, Junfeng Jiang, Xinquan Front Pharmacol Pharmacology Bone defect repair and fracture healing are critical challenges in clinical treatments. Bioactive natural compounds are potential resources for medications for osteogenic effects. We have identified icariin, the effective ingredient of Epimedium pubescens, to promote osteogenic differentiation of bone mesenchymal stem cells (BMSCs) and repair bone defects. To explore more natural compounds with the potential modality for bone repair, in the present study, we employed an icariin-induced gene expression pattern as an osteogenic model and screened the Connectivity Map database for small molecules with gene expression signatures similar to this model. We verified the effectiveness of this molecule docking approach by introducing hydroxycholesterol, the second highest score of the similarity to icariin, into the osteoinductive experiments in vitro and demonstrated its excellent osteogenic effect on BMSCs compared with a BMP-2-positive control group. Based on the compatible result of hydroxycholesterol, subsequently, ginsenoside Rb1 was chosen as the most drug-like natural compound among the molecule docking results from icariin. Finally, ginsenoside Rb1 was demonstrated to promote the expression of osteoblastic genes and ALP activity in vitro and repair the calvarial defect of rats in vivo. The study aimed to provide diverse choices for clinical application in bone repair and functional regeneration. Frontiers Media S.A. 2022-08-24 /pmc/articles/PMC9449150/ /pubmed/36091759 http://dx.doi.org/10.3389/fphar.2022.955983 Text en Copyright © 2022 Wu, Liu, Xu, Zheng, Du, Cao, Shi and Jiang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wu, Yuqiong Liu, Yulan Xu, Yuanjin Zheng, Ao Du, Jiahui Cao, Lingyan Shi, Junfeng Jiang, Xinquan Bioactive natural compounds as potential medications for osteogenic effects in a molecular docking approach |
title | Bioactive natural compounds as potential medications for osteogenic effects in a molecular docking approach |
title_full | Bioactive natural compounds as potential medications for osteogenic effects in a molecular docking approach |
title_fullStr | Bioactive natural compounds as potential medications for osteogenic effects in a molecular docking approach |
title_full_unstemmed | Bioactive natural compounds as potential medications for osteogenic effects in a molecular docking approach |
title_short | Bioactive natural compounds as potential medications for osteogenic effects in a molecular docking approach |
title_sort | bioactive natural compounds as potential medications for osteogenic effects in a molecular docking approach |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449150/ https://www.ncbi.nlm.nih.gov/pubmed/36091759 http://dx.doi.org/10.3389/fphar.2022.955983 |
work_keys_str_mv | AT wuyuqiong bioactivenaturalcompoundsaspotentialmedicationsforosteogeniceffectsinamoleculardockingapproach AT liuyulan bioactivenaturalcompoundsaspotentialmedicationsforosteogeniceffectsinamoleculardockingapproach AT xuyuanjin bioactivenaturalcompoundsaspotentialmedicationsforosteogeniceffectsinamoleculardockingapproach AT zhengao bioactivenaturalcompoundsaspotentialmedicationsforosteogeniceffectsinamoleculardockingapproach AT dujiahui bioactivenaturalcompoundsaspotentialmedicationsforosteogeniceffectsinamoleculardockingapproach AT caolingyan bioactivenaturalcompoundsaspotentialmedicationsforosteogeniceffectsinamoleculardockingapproach AT shijunfeng bioactivenaturalcompoundsaspotentialmedicationsforosteogeniceffectsinamoleculardockingapproach AT jiangxinquan bioactivenaturalcompoundsaspotentialmedicationsforosteogeniceffectsinamoleculardockingapproach |